17 / 66
IMvigor 211: phase III
mUC with progression
during or following
platinum-based CT
-<2 lines
TCC histology as predominant
component
PS 0-1
R
A
N
D
O
M
I
Z
A
T
I
O
N
Atezolizumab 1200 mg IV q3w
Paclitaxel q3w, or
Docetaxel q3w, or
Vinflunine q3w
1:1
Objetivo principal: OS tested
hierarchically in pre-especified
populations
N=931
Stratification factors
No of risk factors (0 vs 1/1/3)
Liver mets (yes vs no)
PD-L1 status (0/1 vs 2/3)
Chemotherapy (vinflunine vs taxanes)
Powles T, et al. Lancet 2017 Dec 18 [epub ahead of print].